TrialAnnals of oncology : official journal of the European Society for Medical Oncology2017

Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial.

R Hui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.